StockData

Corvus Pharmaceuticals vs Spyre Therapeutics

CRVS and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVS and SYRE compare

Spyre Therapeutics is the larger company, worth 9.7 times as much as Corvus Pharmaceuticals ($8.3B against $856M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVSSYRE
Size and price
Market cap$856M$8.3B
Share price$10.17$93.81
Change, 1 year16.0%299%
Change, 5 years198%−41.8%
Beta (5Y)0.651.99
Employees37102
StockData Score
Total score77
Valuation score00
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/B3.8× (better)7.5×
FCF yield−5.3%–
Profitability
Return on equity−35.4%−23.0% (better)
Return on invested capital−564%–
Financial health
Debt / equity0.000.00
Current ratio16.1618.53 (better)
Altman Z-score34.4668.16 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.1%109%
Held by insiders30.5%20.3%
Insider net buying, 12 months$384K (better)−$442M
Short interest, % of float30.4%16.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.